全文获取类型
收费全文 | 4752篇 |
免费 | 468篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 137篇 |
妇产科学 | 105篇 |
基础医学 | 558篇 |
口腔科学 | 77篇 |
临床医学 | 516篇 |
内科学 | 1043篇 |
皮肤病学 | 43篇 |
神经病学 | 257篇 |
特种医学 | 261篇 |
外科学 | 1055篇 |
综合类 | 172篇 |
一般理论 | 2篇 |
预防医学 | 276篇 |
眼科学 | 26篇 |
药学 | 285篇 |
中国医学 | 10篇 |
肿瘤学 | 434篇 |
出版年
2021年 | 49篇 |
2020年 | 37篇 |
2019年 | 58篇 |
2018年 | 51篇 |
2016年 | 58篇 |
2015年 | 65篇 |
2014年 | 93篇 |
2013年 | 104篇 |
2012年 | 144篇 |
2011年 | 160篇 |
2010年 | 119篇 |
2009年 | 103篇 |
2008年 | 149篇 |
2007年 | 183篇 |
2006年 | 137篇 |
2005年 | 150篇 |
2004年 | 164篇 |
2003年 | 150篇 |
2002年 | 144篇 |
2001年 | 161篇 |
2000年 | 160篇 |
1999年 | 123篇 |
1998年 | 91篇 |
1997年 | 90篇 |
1996年 | 106篇 |
1995年 | 82篇 |
1994年 | 69篇 |
1993年 | 67篇 |
1992年 | 149篇 |
1991年 | 154篇 |
1990年 | 150篇 |
1989年 | 173篇 |
1988年 | 137篇 |
1987年 | 117篇 |
1986年 | 119篇 |
1985年 | 100篇 |
1984年 | 93篇 |
1983年 | 83篇 |
1982年 | 61篇 |
1981年 | 49篇 |
1980年 | 57篇 |
1979年 | 75篇 |
1978年 | 50篇 |
1977年 | 63篇 |
1976年 | 55篇 |
1975年 | 47篇 |
1974年 | 54篇 |
1973年 | 40篇 |
1972年 | 46篇 |
1970年 | 36篇 |
排序方式: 共有5272条查询结果,搜索用时 46 毫秒
991.
Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells 总被引:7,自引:0,他引:7
Cyclin D1 and cyclin E are overexpressed in approximately 45% and 30% of breast cancers, respectively, and adverse associations with patient outcome have been reported. The potential roles of cyclin D1 and cyclin E expression as markers of therapeutic responsiveness to the pure steroidal antiestrogen ICI 182780 were investigated using T-47D breast cancer cell lines constitutively overexpressing cyclin D1 or cyclin E. Measurement of S phase fraction, phosphorylation states of the retinoblastoma protein, and cyclin E-cyclin-dependent kinase (Cdk) 2 activity demonstrated that overexpression of cyclin D1 decreased sensitivity to antiestrogen inhibition at 24 and 48 h. Overexpression of cyclin E produced a less pronounced early cell cycle effect indicating only partial resistance to antiestrogen inhibition in the short-term. In ICI 182780-treated cyclin D1-overexpressing cells, sufficient Cdk activity was retained to allow retinoblastoma protein phosphorylation and cell proliferation, despite an increase in the association of p21 and p27 with cyclin D1-Cdk4/6 and cyclin E-Cdk2 complexes. After longer-term (>7 days) treatment, antiestrogens inhibited colony growth in cyclin D1- or cyclin E-overexpressing breast cancer cells, but with an approximately 2-2.5-fold decrease in dose sensitivity. This was associated with a fall in cyclin D1 levels, a reduction in the half-life of cyclin D1 protein and a decline in cyclin E-Cdk2 activity in cyclin D1-overexpressing cells, and the maintenance of cyclin E-p27 association in the cyclin E-overexpressing cells. These data confirm that cyclin D1 expression and cyclin E-p27 association play important roles in antiestrogen action, and suggest that cyclin D1 or cyclin E overexpression has subtle effects on antiestrogen sensitivity. Additional studies to elucidate the contribution of alterations in cyclin D1 stability to antiestrogen action and to assess the relationship between antiestrogen sensitivity and expression of cyclin D1, cyclin E, or p27 in a clinical setting are required. 相似文献
992.
Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1 总被引:3,自引:0,他引:3
Swarbrick A Akerfeldt MC Lee CS Sergio CM Caldon CE Hunter LJ Sutherland RL Musgrove EA 《Oncogene》2005,24(3):381-389
The helix-loop-helix protein Id1 has been implicated in regulating mammary epithelial cell proliferation and differentiation but the underlying molecular mechanisms are not well characterized. Under low serum conditions, ectopic expression of Id1, but not Id2, allowed continued proliferation of immortalized mammary epithelial cells and breast cancer cells. Conversely, downregulation of Id1 impaired proliferation. The effects of short interfering RNA (siRNA)-mediated downregulation of Id1 were the same as those following downregulation of c-Myc: decreased expression of cyclins D1 and E, reduced phosphorylation of pRb at Ser780 (a site targeted by cyclin D1-Cdk4) and reduced cyclin E-Cdk2 activity. Decreased cyclin D1 expression was an early response to Id1 antisense oligonucleotide treatment. Inhibition of c-Myc function by siRNA, antisense oligonucleotides or a dominant repressor resulted in downregulation of Id1, while ectopic expression of c-Myc resulted in rapid induction of Id1, suggesting that Id1 may be downstream of c-Myc. These data indicate that in mammary epithelial cells, Id1 has cell cycle regulatory functions that are similar to those of c-Myc, and suggest that cyclin D1 may be involved in Id1 regulation of cell cycle progression. 相似文献
993.
Clancy JL Henderson MJ Russell AJ Anderson DW Bova RJ Campbell IG Choong DY Macdonald GA Mann GJ Nolan T Brady G Olopade OI Woollatt E Davies MJ Segara D Hacker NF Henshall SM Sutherland RL Watts CK 《Oncogene》2003,22(32):5070-5081
EDD (E3 isolated by differential display), located at chromosome 8q22.3, is the human orthologue of the Drosophila melanogaster tumour suppressor gene 'hyperplastic discs' and encodes a HECT domain E3 ubiquitin protein-ligase. To investigate the possible involvement of EDD in human cancer, several cancers from diverse tissue sites were analysed for allelic gain or loss (allelic imbalance, AI) at the EDD locus using an EDD-specific microsatellite, CEDD, and other polymorphic microsatellites mapped in the vicinity of the 8q22.3 locus. Of 143 cancers studied, 38 had AI at CEDD (42% of 90 informative cases). In 14 of these cases, discrete regions of imbalance encompassing 8q22.3 were present, while the remainder had more extensive 8q aberrations. AI of CEDD was most frequent in ovarian cancer (22/47 informative cases, 47%), particularly in the serous subtype (16/22, 73%), but was rare in benign and borderline ovarian tumours. AI was also common in breast cancer (31%), hepatocellular carcinoma (46%), squamous cell carcinoma of the tongue (50%) and metastatic melanoma (18%). AI is likely to represent amplification of the EDD gene locus rather than loss of heterozygosity, as quantitative RT-PCR and immunohistochemistry showed that EDD mRNA and protein are frequently overexpressed in breast and ovarian cancers, while among breast cancer cell lines EDD overexpression and increased gene copy number were correlated. These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression. 相似文献
994.
p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells 总被引:2,自引:0,他引:2
Carroll JS Lynch DK Swarbrick A Renoir JM Sarcevic B Daly RJ Musgrove EA Sutherland RL 《Cancer research》2003,63(15):4322-4326
Tamoxifen, a selective estrogen-receptor modulator, is effective in the treatment and prevention of breast cancer, but therapeutic resistance is common. Pure steroidal antiestrogens are efficacious in tamoxifen-resistant disease and, unlike tamoxifen, arrest cells in a state of quiescence from which they cannot reenter the cell cycle after growth factor stimulation. We now show that in hydroxytamoxifen-treated cells, transduction of the cell cycle inhibitor p27(Kip1) induces quiescence and insensitivity to growth stimulation by insulin/insulin-like growth factor I and epidermal growth factor/transforming growth factor alpha. Furthermore, reinitiation of cell cycle progression by insulin/insulin-like growth factor I in hydroxytamoxifen-arrested cells involves dissociation of the corepressors nuclear receptor corepressor (N-CoR) and silencing mediator for retinoid and thyroid hormone receptor (SMRT) from nuclear estrogen receptor alpha and redistribution to the cytoplasm, a process that is inhibited by mitogen-activated protein/extracellular signal-regulated kinase, but not phosphatidylinositol 3'-kinase, inhibitors. These data suggest that agents that up-regulate p27(Kip1) or inhibit growth factor signaling via the extracellular signal-regulated kinases should be tested as therapeutic strategies in tamoxifen-resistant breast cancer. 相似文献
995.
Smith LM Nesterova A Ryan MC Duniho S Jonas M Anderson M Zabinski RF Sutherland MK Gerber HP Van Orden KL Moore PA Ruben SM Carter PJ 《British journal of cancer》2008,99(1):100-109
CD133/prominin-1 is a pentaspan transmembrane glycoprotein overexpressed in various solid tumours including colorectal and glioblastomas. CD133 was found here to be highly expressed in >or=50% of pancreatic, gastric and intrahepatic cholangiocarcinomas. Quantitative flow cytometric analysis showed that a panel of established hepatocellular, pancreatic and gastric cancer cell lines expressed CD133 at levels higher than normal epithelial cells or bone marrow progenitor cells. A murine anti-human CD133 antibody (AC133) conjugated to a potent cytotoxic drug, monomethyl auristatin F (MMAF), effectively inhibited the growth of Hep3B hepatocellular and KATO III gastric cancer cells in vitro with IC(50) values of 2-7 ng ml(-1). MMAF induced apoptosis in the cancer cells as measured by caspase activation. The anti-CD133-drug conjugate (AC133-vcMMAF) was shown to internalise and colocalised with the lysosomal marker CD107a in the sensitive cell lines. In contrast, in the resistant cell line Su.86.86, the conjugate internalised and colocalised with the caveolae marker, Cav-1. Addition of ammonium chloride, an inhibitor of lysosomal trafficking and processing, suppressed the cytotoxic effect of AC133-vcMMAF in both Hep3B and KATO III. Anti-CD133-drug conjugate treatment resulted in significant delay of Hep3B tumour growth in SCID mice. Anti-CD133 antibody-drug conjugates warrant further evaluation as a therapeutic strategy to eradicate CD133+ tumours. 相似文献
996.
997.
Colour Doppler velocity imaging of the myocardium. 总被引:31,自引:0,他引:31
W N McDicken G R Sutherland C M Moran L N Gordon 《Ultrasound in medicine & biology》1992,18(6-7):651-654
A technique has been developed for producing images of the velocity of tissue motion within the myocardium. It has been demonstrated that Colour Flow Doppler imagers can be operated to depict the velocities within the myocardium rather than moving blood in the cardiac chambers. The technique exhibits the normal advantages of diagnostic ultrasound, i.e., real-time imaging with relatively inexpensive equipment and no hazard to the patient. Further work requires to be done to determine the optimum signal processing algorithms for moving tissue echoes and to ascertain whether the technique is of value in clinical applications. 相似文献
998.
Down's syndrome in South Australia. 总被引:5,自引:0,他引:5
In a survey of Down's syndrome in South Australia, 921 persons, both living and deceased, were identified; 717 individuals with the disorder were living in South Australia. Cytogenetic confirmation of the diagnosis had been made in 774 cases. From 1955 to 1977, the over-all incidence of Down's syndrome at birth was found to be 1.175/1000 live births. The incidence of Down's syndrome was significantly lower over the last five years of this period than for the first 18 years; thus it appears that the incidence of Down's syndrome in South Australia is falling. Analysis of maternal age changes with time has not revealed any changes to the maternal age-specific rates for Down's syndrome, although the rate for mothers aged 25 years or younger appears to be falling. The proportion of Down's syndrome babies born to women aged 35 years or more has decreased from 65.7% for those born before 1950 to 30.4% for those born from 1975 to 1977; similarly, the median maternal age has fallen from 37.12 years to 28.25 years. Regression analyses of maternal age rates for Down's syndrome by single years have produced figures suitable for genetic counselling. A plea is made that Down's syndrome should become a notifiable condition. 相似文献
999.
Beta-lactamase inhibitors and reversal of antibiotic resistance 总被引:2,自引:0,他引:2
R Sutherland 《Trends in pharmacological sciences》1991,12(6):227-232
The resistance of bacteria to beta-lactam antibiotics is usually associated with production of the enzyme, beta-lactamase, which inactivates the beta-lactam molecule. In the long search for inhibitors of bacterial beta-lactamase the first clinically useful agent, clavulanic acid, was isolated as a metabolite of Streptomyces clavuligerus. Robert Sutherland describes the background to the demonstration of clinical efficacy of combinations of clavulanic acid and other agents with penicillins which has confirmed beta-lactamase inhibitors as one solution to the problems posed by beta-lactamase-producing bacteria. 相似文献
1000.